PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Assessing the recovery from prerenal and renal acute kidney injury after treatment with single herbal medicine via activity of the biomarkers HMGB1, NGAL and KIM-1 in kidney proximal tubular cells treated by cisplatin with different doses and exposure times.

Abstract Acute kidney injury (AKI) is an initial factor in many kidney disorders. Pre- and intra-renal AKI biomarkers have recently been reported. Recovery from AKI by herbal medicine has rarely been reported. Thus, this study aimed to investigate the dose- and time-dependent effects of herbal medicines to protect against AKI in cisplatin-induced human kidney 2 (HK-2) cells by assessing the activities of high-mobility group box protein 1 (HMGB1), neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1).
PMID
Related Publications

Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.

Clinical implication of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in patients with acute paraquat intoxication.

Performance of Serum Creatinine and Kidney Injury Biomarkers for Diagnosing Histologic Acute Tubular Injury.

Diagnostic performance of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidney injury in an obstructive nephropathy patient.

Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.

Authors

Mayor MeshTerms
Keywords

Acute kidney injury

Herbal medicine

High-mobility group box protein 1

Kidney injury molecule-1

Neutrophil gelatinase-associated lipocalin

Journal Title bmc complementary and alternative medicine
Publication Year Start




PMID- 29258482
OWN - NLM
STAT- MEDLINE
DCOM- 20180108
LR  - 20180108
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Dec 19
TI  - Assessing the recovery from prerenal and renal acute kidney injury after
      treatment with single herbal medicine via activity of the biomarkers HMGB1, NGAL 
      and KIM-1 in kidney proximal tubular cells treated by cisplatin with different
      doses and exposure times.
PG  - 544
LID - 10.1186/s12906-017-2055-y [doi]
AB  - BACKGROUND: Acute kidney injury (AKI) is an initial factor in many kidney
      disorders. Pre- and intra-renal AKI biomarkers have recently been reported.
      Recovery from AKI by herbal medicine has rarely been reported. Thus, this study
      aimed to investigate the dose- and time-dependent effects of herbal medicines to 
      protect against AKI in cisplatin-induced human kidney 2 (HK-2) cells by assessing
      the activities of high-mobility group box protein 1 (HMGB1), neutrophil
      gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1).
      METHODS: Proximal tubular HK-2 cell lines were treated with either 400 muM of
      cisplatin for 6 h or 10 muM of cisplatin for 24 h and then exposed to ten types
      of single herbal medicines, including Nelumbo nymphaea (NY) at a dose of 100
      mug/mL. The AKI biomarkers HMGB1, NGAL and KIM-1 were repeatedly measured by an
      ELISA assay at 2, 4, and 6 h in the group treated with 400 muM of cisplatin to
      confirm necrotic cell death and at 6, 24, and 48 h in the group treated with 10
      muM of cisplatin to examine apoptotic cell death. Recovery confirm was conducted 
      through in vivo study using ICR mice for 3 day NY or Paeonia suffruticosa intake.
      RESULTS: Cisplatin treatment at a concentration of 10 muM decreased cell
      viability. Treatment with 400 muM of cisplatin reduced HMBG1 activity and
      resulted in lactate dehydrogenase release. In longer exposure durations (up to 48
      h), NGAL and KIM-1 exhibited activity from 24 h onward. Additionally, NY
      treatment resulted in an approximately 50% change in all three biomarkers. The
      time-dependent profiles of HMGB1, NGAL and KIM-1 activities up to 48 h were
      notably different; HMGB1 exhibited a 7-fold change at 6 h, and NGAL and KIM-1
      exhibited 1.7-fold changes at 24 h, respectively. Consistently, serum and urine
      NGAL and KIM-1 activities were all reduced in ICR mice. CONCLUSIONS: Several
      single herbal medicines, including NY, have a potential as effectors of AKI due
      to their ability to inhibit the activation of HMGB1, NGAL and KIM-1 in an in
      vitro AKI-mimicked condition and simple in vivo confirm. Furthermore, an in vivo 
      proof-of-concept study is needed.
FAU - Oh, Sung-Man
AU  - Oh SM
AD  - The K-herb Research Center, Korea Institute of Oriental Medicine, 1672
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Park, Gunhyuk
AU  - Park G
AD  - The K-herb Research Center, Korea Institute of Oriental Medicine, 1672
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Lee, Seung Hoon
AU  - Lee SH
AD  - The K-herb Research Center, Korea Institute of Oriental Medicine, 1672
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Seo, Chang-Seob
AU  - Seo CS
AD  - The K-herb Research Center, Korea Institute of Oriental Medicine, 1672
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Shin, Hyeun-Kyoo
AU  - Shin HK
AD  - The K-herb Research Center, Korea Institute of Oriental Medicine, 1672
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Oh, Dal-Seok
AU  - Oh DS
AUID- ORCID: http://orcid.org/0000-0002-7705-6593
AD  - The K-herb Research Center, Korea Institute of Oriental Medicine, 1672
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea. [email protected]
LA  - eng
GR  - HI16C0948/Korea Health Industry Development Institute/Republic of Korea
PT  - Journal Article
DEP - 20171219
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (HAVCR1 protein, human)
RN  - 0 (HMGB1 Protein)
RN  - 0 (Hepatitis A Virus Cellular Receptor 1)
RN  - 0 (Lipocalin-2)
RN  - 0 (Plant Preparations)
RN  - 0 (Protective Agents)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Acute Kidney Injury/chemically induced/*drug therapy/physiopathology
MH  - Animals
MH  - Cell Death/drug effects
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Cisplatin/adverse effects
MH  - HMGB1 Protein/metabolism
MH  - Hepatitis A Virus Cellular Receptor 1/metabolism
MH  - Humans
MH  - Lipocalin-2/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Plant Preparations/*pharmacology/*therapeutic use
MH  - Protective Agents/*pharmacology/*therapeutic use
PMC - PMC5738030
OTO - NOTNLM
OT  - Acute kidney injury
OT  - Herbal medicine
OT  - High-mobility group box protein 1
OT  - Kidney injury molecule-1
OT  - Neutrophil gelatinase-associated lipocalin
EDAT- 2017/12/21 06:00
MHDA- 2018/01/09 06:00
CRDT- 2017/12/21 06:00
PHST- 2017/08/14 00:00 [received]
PHST- 2017/12/07 00:00 [accepted]
PHST- 2017/12/21 06:00 [entrez]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
AID - 10.1186/s12906-017-2055-y [doi]
AID - 10.1186/s12906-017-2055-y [pii]
PST - epublish
SO  - BMC Complement Altern Med. 2017 Dec 19;17(1):544. doi: 10.1186/s12906-017-2055-y.